SRR12202468
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.580
- KRAS_SIGNALING_DN+0.310
- ALLOGRAFT_REJECTION+0.230
- SPERMATOGENESIS+0.220
- COAGULATION+0.190
- KRAS_SIGNALING_UP+0.160
- OXIDATIVE_PHOSPHORYLATION+0.100
- IL6_JAK_STAT3_SIGNALING+0.060
- INFLAMMATORY_RESPONSE+0.060
- ANDROGEN_RESPONSE+0.040
Top 10 suppressed
- MITOTIC_SPINDLE-0.540
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.440
- MYC_TARGETS_V2-0.430
- WNT_BETA_CATENIN_SIGNALING-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.380
- NOTCH_SIGNALING-0.360
- DNA_REPAIR-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- UV_RESPONSE_DN-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1465337 | GTEX | — | 0.927 |
| 2 | SRR1320892 | GTEX | — | 0.868 |
| 3 | SRR1360150 | GTEX | — | 0.858 |
| 4 | MNG506 | — | — | 0.850 |
| 5 | MNG543 | — | — | 0.843 |
| 6 | MDT-AP-0839 | Med | Medulloblastoma | 0.831 |
| 7 | TCGA-78-7166-01A-12R-2066-07 | — | cohortA4 | 0.830 |
| 8 | SRR1323764 | GTEX | — | 0.829 |
| 9 | TCGA-49-4514-01A-21R-1858-07 | — | cohortA4 | 0.828 |
| 10 | MNG860 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.580 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |